<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05072938</url>
  </required_header>
  <id_info>
    <org_study_id>MUC0S-P401</org_study_id>
    <nct_id>NCT05072938</nct_id>
  </id_info>
  <brief_title>Phase IV Clinical Trial to Compare the Efficacy and Safety of Rebamipide/Nizatidine Combination Therapy With Nizatidine Monotherapy in Patients With Gastritis</brief_title>
  <official_title>A Multi-center, Open-label, Randomized, Phase IV Clinical Trial to Compare the Efficacy and Safety of Rebamipide/Nizatidine Combination Therapy With Nizatidine Monotherapy in Patients With Gastritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the Efficacy and Safety of Rebamipide/Nizatidine&#xD;
      Combination Therapy with Nizatidine Monotherapy in Patients with Gastritis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the Efficacy and Safety of Rebamipide/Nizatidine&#xD;
      Combination Therapy with Nizatidine Monotherapy in Patients with Gastritis.&#xD;
&#xD;
      Anticipated result is to prove superiority of Rebamipide/Nizatidine combination therapy at 2&#xD;
      weeks compared to Nizatidine Monotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effective rate of gastric mucosal erosion on the upper gastrointestinal endoscopy at 2 weeks from baseline</measure>
    <time_frame>At 2 weeks</time_frame>
    <description>Pearson's chi-square test or Fisher's exact test will be used to compare the effective rate between two groups</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Gastritis</condition>
  <arm_group>
    <arm_group_label>Nizatidine Monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nizatidine Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rebamipide/Nizatidine Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rebamipide/Nizatidine Combination Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mucotra SR Tablet 150mg</intervention_name>
    <description>Rebamipide/Nizatidine Combination Therapy</description>
    <arm_group_label>Rebamipide/Nizatidine Combination Therapy</arm_group_label>
    <other_name>Mucotra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axid Capsule 150mg</intervention_name>
    <description>Nizatidine Monotherapy</description>
    <arm_group_label>Nizatidine Monotherapy</arm_group_label>
    <other_name>Axid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged 19 years or older and under 75 years&#xD;
&#xD;
          2. Subject who was diagnosed with acute or chronic gastritis in upper gastrointestinal&#xD;
             endoscopy conducted within 7 days prior to the start of administration of medications&#xD;
             for clinical trials and identified at least one labyrinth (defect of mucosal surface&#xD;
             layer)&#xD;
&#xD;
          3. Subject who voluntarily decides to participate in the trial after hearing the&#xD;
             explanation of this clinical trial and signs the informed consent form.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Subject who is unable to examine the upper gastrointestinal endoscope&#xD;
&#xD;
          2. A person with the following past history&#xD;
&#xD;
               -  Surgery to suppress gastric acid secretion or gastrointestinal and esophagus&#xD;
                  surgery&#xD;
&#xD;
               -  Malignant tumor of the digestive system&#xD;
&#xD;
               -  overreacted to the components of medicine for clinical trials and H2 receptor&#xD;
                  blockers&#xD;
&#xD;
               -  Drug or alcohol abuse&#xD;
&#xD;
          3. A person accompanied by the following diseases&#xD;
&#xD;
               -  Digestive ulcers (excluding half a scar)&#xD;
&#xD;
               -  Reflux esophagitis&#xD;
&#xD;
               -  Inflammatory bowel disease (cron disease, ulcerative colitis)&#xD;
&#xD;
               -  Thrombotic diseases (such as cerebral thrombosis, myocardial infarction,&#xD;
                  thrombotic venous inflammation, etc.)&#xD;
&#xD;
               -  Zollinger-Ellison syndrome&#xD;
&#xD;
               -  Subject with mental illness, cardiovascular system, respiratory system, endocrine&#xD;
                  system, central nervous system who the investigator determined that it is&#xD;
                  difficult to participate in this clinical trial&#xD;
&#xD;
          4. A person who needs to administer a taboo drug during the clinical trial period.&#xD;
&#xD;
          5. Pregnant women and nursing women&#xD;
&#xD;
          6. Fertilized women and men who have a pregnancy plan or do not have the will to use the&#xD;
             appropriate contraceptive method during the clinical trial period.&#xD;
&#xD;
          7. Subject with genetic problems such as galactose intolerance, Lapp lactase deficiency,&#xD;
             glucose-galactose malabsorption, etc.&#xD;
&#xD;
          8. Severe liver disorder (AST or ALT &gt; 3 times the normal upper limit of the organ)&#xD;
&#xD;
          9. Serious nephropathy (creatinine clearance &lt; 50 mL/min)&#xD;
&#xD;
         10. Subject who has been administered (applied) other clinical medications or medical&#xD;
             devices within 4 weeks of screening&#xD;
&#xD;
         11. Subject who the investigator determined it is inappropriate to participate in this&#xD;
             clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nizatidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

